Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | BCL9 | O00512 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381950 | 0.85 | MEN1 (0.45) | MGLLDRD2DRD1DRD4DRD5 | |
| SCHEMBL23211936 | 0.81 | NOTUM (0.52) | NOTUMMGLLDRD2DRD1DRD4 | |
| SCHEMBL21381632 | 0.81 | NOTUM (0.52) | NOTUMMGLLDRD2DRD1DRD4 | |
| SCHEMBL30567993 | 0.78 | PDE4B (0.53) | MGLLBCL9CTNNB1 | |
| SCHEMBL30567996 | 0.78 | PDE4B (0.53) | MGLLBCL9CTNNB1 | |
| SCHEMBL21384745 | 0.78 | PDE4B (0.53) | MGLLBCL9CTNNB1 | |
| SCHEMBL23212068 | 0.78 | PDE4B (0.53) | MGLLBCL9CTNNB1 | |
| SCHEMBL942295 | 0.77 | EPHX2 (0.47) | MGLLHSD11B1FAAHMAPK7MEN1 | |
| SCHEMBL25864470 | 0.75 | GPR119 (0.52) | MGLLHCRTR2HSD11B1BCL9CTNNB1 | |
| SCHEMBL22638731 | 0.75 | HTR2C (0.42) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | NOTUM 70/4885MGLL 1/4885DRD2 3496/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | NOTUM 70/4885MGLL 1/4885DRD2 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.